Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osivelotor Phase 2/3 study in adults and adolescents with sickle cell disease
2023-508766-14-00Phase 3Authorised
- Sponsor
- Global Blood Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of osivelotor in sickle cell disease (SCD) (5 arms), sponsored by Global Blood Therapeutics. Planned start Oct 2026; status: authorised.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2023-508766-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508766-14-00.